Shiroh Tanoue

Dr. Shiroh Tanoue

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
HIHiromichi Iwaya
Hiromichi Iwaya
ATAkihide Tanimoto
Akihide Tanimoto
KTKoshiro Toyodome
Koshiro Toyodome
IKIssei Kojima
Issei Kojima
MHMakoto Hinokuchi
Makoto Hinokuchi
AIAkio Ido
Akio Ido
This study evaluated the feasibility and clinical utility of liquid-based cytology (LBC) specimens via endoscopic ultrasound–guided fine-needle biopsy (EUS-FNB) for next-generation sequencing (NGS) of pancreatic cancer (PC). We prospectively evaluated the performance of DNA extraction and NGS using EUS-FNB samples obtained from PC. Thirty-three consecutive patients with PC who underwent EUS-FNB at our hospital were enrolled. DNA samples were obtained from 96.8% of the patients. When stratified with a variant allele frequency (VAF) > 10% tumor burden, the NGS success rate was 76.7% (n = 23) in formalin-fixed paraffin-embedded (FFPE), 83.3% (n = 25) in LBC, and 76.7% (n = 23) in frozen samples. The overall NGS success rate was 86.7% (n = 26) using FFPE, LBC, or frozen samples. The detection rates for the main mutated genes were as follows: 86.7% for KRAS, 73.3% for TP53, 66.7% for CDKN2A, 36.7% for SMAD4, and 16.7% for ARID1A. LBC had the highest median value of VAF (23.5%) for KRAS and TP53. PC mutation analysis using NGS was successfully performed using LBC compared with FFPE and frozen samples. This approach provides an alternative and affordable source of molecular testing materials.

1 June 2022 in Auris Nasus Larynx
Verified
Journal Article
Closed access
HMHidehito Maeda
Hidehito Maeda
FSFumisato Sasaki
Fumisato Sasaki
MKMasayuki Kabayama
Masayuki Kabayama
HIHiromichi Iwaya
Hiromichi Iwaya
YKYuga Komaki
Yuga Komaki
AIAkio Ido
Akio Ido

28 April 2021 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
HYHaruhito Yoshimine
Haruhito Yoshimine
STShiroh Tanoue
Shiroh Tanoue
YIYutaro Ibi
Yutaro Ibi
MMMasato Minami
Masato Minami
MNMai Nakahara
Mai Nakahara
AIAkio Ido
Akio Ido

7 June 2021 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MKMasaya Kozono
Masaya Kozono
STShiroh Tanoue
Shiroh Tanoue
KKKanna Kiyama
Kanna Kiyama
KJKenichi Jikuya
Kenichi Jikuya
MKMachiko Kawahira
Machiko Kawahira
AIAkio Ido
Akio Ido

20 June 2024 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
YHYoshifumi Hidaka
Yoshifumi Hidaka
STShiroh Tanoue
Shiroh Tanoue
TATakuro Ayukawa
Takuro Ayukawa
KTKoji Takumi
Koji Takumi
HNHirotsugu Noguchi
Hirotsugu Noguchi
CKChihaya Koriyama
Chihaya Koriyama
Background: Pancreatic ductal occlusion can accompany pancreatic head cancer, leading to pancreatic exocrine insufficiency (PEI) and adverse effects on nutritional status and postoperative outcomes. We investigated its impact on nutritional status, body composition, and postoperative outcomes in patients with pancreatic head cancer undergoing neoadjuvant therapy (NAT). Methods: We analyzed 136 patients with pancreatic head cancer who underwent NAT prior to intended pancreaticoduodenectomy (PD) between 2015 and 2022. Nutritional and anthropometric indices (body mass index [BMI], albumin, prognostic nutritional index [PNI], Glasgow prognostic score, psoas muscle index, subcutaneous adipose tissue index [SATI], and visceral adipose tissue index) and postoperative outcomes were compared between the occlusion (n = 78) and non-occlusion (n = 58) groups, in which 61 and 44 patients, respectively, ultimately underwent PD. Results: The occlusion group showed significantly lower post-NAT BMI, PNI, and SATI (p = 0.011, 0.005, and 0.015, respectively) in the PD cohort. The occlusion group showed significantly larger main pancreatic duct, smaller pancreatic parenchyma, and greater duct–parenchymal ratio (p < 0.001), and these morphological parameters significantly correlating with post-NAT nutritional and anthropometric indices. Postoperative 3-year survival and recurrence-free survival (RFS) rates were significantly poorer (p = 0.004 and 0.013) with pancreatic ductal occlusion, also identified as an independent postoperative risk factor for overall survival (hazard ratio [HR]: 2.31, 95% confidence interval [CI] 1.08–4.94, p = 0.030) and RFS (HR: 2.03, 95% CI 1.10–3.72, p = 0.023), in multivariate analysis. Conclusions: Pancreatic ductal occlusion may be linked to poorer postoperative outcomes due to PEI-related malnutrition.

1 November 2024 in Cancer Research Communications
Verified
Journal Article
Open access
TWTakeshi Watanabe
Takeshi Watanabe
VNVan Tien Nguyen
Van Tien Nguyen
SKSakurako Katsuura-Kamano
Sakurako Katsuura-Kamano
KAKokichi Arisawa
Kokichi Arisawa
MIMasashi Ishizu
Masashi Ishizu
Keitaro MatsuoKeitaro Matsuo
Keitaro Matsuo
The present study investigated the relationship between metabolic phenotypes and the risk of cancer in a Japanese population using the criteria of metabolic phenotypes based on an examination and those based on questionnaires. We used data from 25,357 subjects for examination-based analyses and those from 53,042 subjects for questionnaire-based analyses in the Japan Multi-institutional Collaborative Cohort study. Metabolic phenotypes were defined by classifying subjects according to their body mass index (BMI; obesity: BMI ≥25 kg/m2; normal weight: BMI <25 kg/m2) and the number of metabolic abnormalities. Metabolic abnormalities were defined according to metabolic syndrome components of the Joint Interim Statement criteria for examination-based analyses and self-reported histories of diabetes, dyslipidemia, and hypertension for questionnaire-based analyses. Cox proportional hazards regression analyses adjusted for potential confounders were performed for total and site-specific cancer incidence rates according to metabolic phenotypes. Metabolically unhealthy obesity (MUHO) was significantly associated with cancer incidence in both examination-based [HR (95% confidence interval), 1.17 (1.01–1.36)] and questionnaire-based analyses [HR (95% confidence interval), 1.15 (1.04–1.26)]. Regarding site-specific cancer in questionnaire-based analyses, metabolically healthy obesity and MUHO were associated with colorectum and liver cancers in all subjects and with breast cancer in female subjects. Subjects with a metabolically unhealthy normal weight had a higher risk of pancreatic cancer. Moreover, MUHO was associated with corpus uteri cancer in female subjects. This prospective cohort study suggests that metabolic phenotypes are important risk factors for total and some site-specific cancers in Japanese adults. Significance: The prospective cohort study in a large Japanese population suggested that metabolic phenotypes are important risk factors for total and some site-specific cancers in Japanese adults. Moreover, the risk of each site-specific cancer may differ according to metabolic phenotypes.